Prosecution Insights
Last updated: April 19, 2026
Application No. 18/757,999

Medicament Delivery Device and Actuation Mechanism for a Drug Delivery Device

Non-Final OA §112
Filed
Jun 28, 2024
Examiner
MEDWAY, SCOTT J
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Sanofi-Aventis Deutschland GmbH
OA Round
4 (Non-Final)
67%
Grant Probability
Favorable
4-5
OA Rounds
3y 9m
To Grant
90%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allow Rate
583 granted / 871 resolved
-3.1% vs TC avg
Strong +23% interview lift
Without
With
+23.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
52 currently pending
Career history
923
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
44.4%
+4.4% vs TC avg
§102
25.9%
-14.1% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 871 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Examiner acknowledges the reply filed 11/20/2025. Claims 2-12, 14-16, 18-20, 22 and 27 were amended. Claims 33-37 were newly added. The amendment was accompanied by Remarks, the contents of which are addressed in the Response to Arguments section of this Office action. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 12, 15, 22 and 27, and all claims depending therefrom, are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claims 2, 15, 22 and 27, the new matter is that the auto-injector is configured to automatically deliver a dose of medicament from the auto-injector upon the inner part moving to a predetermined position relative to the housing. This feature is not disclosed in the original disclosure with specificity necessary for a person of ordinary skill in the art to conclude that the Applicant possessed this invention at the time of filing. Although the original disclosure discusses that "the delivery device 1 is an autoinjector designed to automatically deliver a dose of a medicament by means of a needle 2 upon sleeve-driven actuation" (see specification at para [0089]). But the original disclosure does not disclose specifically automatically delivering a dose of medicament when the inner part moves to a predetermined position relative to the housing. Response to Arguments Applicant's arguments filed 11/20/2025 have been fully considered. A new ground of rejection has been applied to the pending independent claims. While the claims were amended to incorporate the rejected feature, this feature was recited in a previous claim set(s) but was not rejected at the time of consideration of the previous claim set(s). For this reason, this action has been made NON-FINAL. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SCOTT J MEDWAY whose telephone number is (571)270-3656. The examiner can normally be reached Monday through Friday, 8:30 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at (571) 270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SCOTT J MEDWAY/Primary Examiner, Art Unit 3783 03/04/2026
Read full office action

Prosecution Timeline

Jun 28, 2024
Application Filed
Dec 20, 2024
Non-Final Rejection — §112
Mar 27, 2025
Response Filed
Apr 16, 2025
Final Rejection — §112
May 02, 2025
Response after Non-Final Action
May 23, 2025
Request for Continued Examination
May 29, 2025
Response after Non-Final Action
Sep 23, 2025
Non-Final Rejection — §112
Nov 04, 2025
Examiner Interview (Telephonic)
Nov 04, 2025
Examiner Interview Summary
Nov 20, 2025
Response Filed
Mar 05, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594374
STACKABLE MANIFOLDS FOR MEDICAL FLUIDS
2y 5m to grant Granted Apr 07, 2026
Patent 12558480
METHODS AND SYSTEMS FOR FILLING IV BAGS WITH THERAPEUTIC FLUID
2y 5m to grant Granted Feb 24, 2026
Patent 12551683
NEEDLELESS CONNECTOR AND ACCESS PORT DISINFECTION CLEANER AND ANTIMICROBIAL PROTECTION CAP
2y 5m to grant Granted Feb 17, 2026
Patent 12544506
INFUSION SET AND INSERTER ASSEMBLY SYSTEMS AND METHODS
2y 5m to grant Granted Feb 10, 2026
Patent 12533467
Medicament Delivery Device and Actuation Mechanism for a Drug Delivery Device
2y 5m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

4-5
Expected OA Rounds
67%
Grant Probability
90%
With Interview (+23.4%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 871 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month